Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants as established by medical history and clinical examination before entering the study.~* Age: 6-8 weeks at the time of enrollment.~* Parental ability and willingness to provide informed consent.~* Parent who intends to remain in the area with the child during the study period.~Exclusion Criteria:~* Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment (temporary exclusion)~* Presence of fever on the day of enrollment (temporary exclusion).~* Acute disease at the time of enrollment (temporary exclusion)~* Concurrent participation in another clinical trial throughout the entire timeframe for this study.~* Presence of significant malnutrition (weight-for-height z-score \<-3SD median) or any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would compromise the subject's health or is likely to result in nonconformance to the protocol. History of congenital abdominal disorders, intussusception or abdominal surgery~* Known or suspected impairment of immunological function based on medical history and physical examination.~* Household contact with an immunosuppressed individual or pregnant woman.~* Prior receipt of rotavirus vaccine.~* A known sensitivity or allergy to any components of the study vaccine.~* Major congenital or genetic defect.~* History of persistent diarrhea (defined as diarrhea more than 14 days).~* Participant's parents not able, available or willing to accept active weekly follow-up by the study staff.~* Has received any immunoglobulin therapy and/or blood products since birth or planned administration during the study period.~* History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study.~* History of any neurologic disorders or seizures.~* Any medical condition in the parents/infant which, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parents' ability to give informed consent.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- Vaccine Arm (Type: EXPERIMENTAL): 3 doses, 4 weeks apart, of Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
- Placebo group (Type: PLACEBO_COMPARATOR): 3 doses, 4 weeks apart, of Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete